• Slider Image
  • Slider Image
  • Slider Image

In the Press

January 22, 2018

Uncertain federal budget curtails research hiring in San Diego

Even with the anticipated passage of a temporary federal budget, biomedical research still faces an uncertain future, says UC San Diego cancer researcher David Cheresh. David Cheresh, PhD.

January 8, 2018

Celgene to buy San Diego cancer-drug maker Impact for $1.1B

Celgene Corp. agreed to buy closely held San Diego-based Impact Biomedicines for $1.1 billion upfront to gain an experimental blood cancer treatment, with founder Dr. Catriona Jamieson.

January 4, 2018

Physical activity may improve cognitive function among breast cancer survivors

Increased physical activity improved cognitive function among a cohort of breast cancer survivors who were 2 years beyond surgery, according to study results by senior author Sheri Hartman,.

December 20, 2017

Aggressive Treatment of Early Lung Cancer Improves Survival

Aggressive surgery for early-stage NSCLC results in longer survival than more moderate surgery and an increasingly popular radiation therapy approach, according to a study by senior author James Murphy, MD.

December 6, 2017

Fate Therapeutics, UC San Diego Launch CAR NK Cancer Immunotherapy Collaboration

The collaboration will develop off-the-shelf, chimeric antigen receptor (CAR)-targeted natural killer (NK) cell cancer immunotherapies, led by Dan Kaufman, MD, PhD.

December 5, 2017

Dynavax Co-founder Takes Long View on Vaccine Development

The FDA approved a new haptatis B vaccine last month, the first Dynavax product to win FDA approval, founded by Dr. Dennis Carson.

December 5, 2017

In Multiple Myeloma, High Levels of Enzyme ADAR1 are Associated with Reduced Survival

Inhibiting ADAR1 in experimental models reduced disease recurrence in an approach known as “precision regenerative medicine”, in a Nature Communications paper with senior authors Drs. Leslie Crews and Catriona Jamieson.

December 1, 2017

State’s Stem Cell Agency Awards Nearly $8 Million for New Leukemia Therapies

UC San Diego researchers will specifically target acute myeloid leukemia, awarded to Drs. Dan Kaufman and Catriona Jamieson.

December 1, 2017

New Cancer Management Guidelines for Care of People with Kaposi Sarcoma

New NCCN guidelines for patients living with HIV who develop AIDS-related Kaposi sarcoma were developed with leadership by Panel Co-Chair Dr. Erin Reid.

November 30, 2017

Vulnerability Identified for Subtypes of Glioblastoma

Precision medicine approach may give previously tested drug a second chance, in a Cancer Cell paper led by senior author David Cheresh, PhD.

November 27, 2017

Immunotherapy Research for Head and Neck Cancers Gets Boost from V Foundation Grant

A team of researchers studying new drugs designed to break resistance to cancer immunotherapy has been awarded a V Foundation for Cancer Research translational grant of $600,000 over three years, led by Judy Varner, PhD.

November 21, 2017

Frontline Cancer: A one-size-fits-all strategy doesn't work fighting cancer

How will the funding for the the U.S. Cancer Moonshot initiative and 21st Century Cures Act be utilized in research, treatment, and prevention, questions Dr. Scott Lippman.

November 14, 2017

A New Strategy for Prevention of Liver Cancer Development

A synthetic double-stranded RNA has potential for use as an anti-liver cancer vaccine, featuring senior author Gen-Sheng Feng, PhD.

November 8, 2017

Precision medicine clinical decision support system bests oncologists at picking cancer treatment

A prominent academic medical center, a supercomputer and a California start-up came together to determine the best regimen for a patient after doctors had tried four previous times, featuring Dr. Razelle Kurzrock.

November 8, 2017

How Chronic Inflammation Tips the Balance of Immune Cells to Promote Liver Cancer

Study explains success of some types of cancer immunotherapy, provides new targets for the development of additional immunotherapies, with senior author Dr. Michael Karin.

November 1, 2017

The Forever War

A new Lancet commission report is both expansive and remarkably detailed, providing a roadmap with directions and 13 priority areas related to, among other things, early detection, immunotherapy, imaging, surgery, drug access, treatment disparities and prevention for cancer, says Dr. Scott Lippman.

October 27, 2017

What a Person's Immune System Says About Their Cancer

UC San Diego School of Medicine researchers have discovered early evidence that the genetics of a person’s immune system may help predict what that person’s cancer might look like, molecularly speaking, with lead author Hannah Carter, PhD.

October 27, 2017

Discussing Treatment Options in Thyroid Cancer

The hype of personalized medicine now is making its way into thyroid cancer, says Dr. Gregory Daniels, and a genetic-based approach to treatment may be in the future for this disease.

October 27, 2017

Recurrent Head and Neck Cancer: Continuing Encouraging Results for Pembrolizumab

Improved outcomes in subset of recurrent head and neck cancer patients with PD-LI-expressing tumors featuring the study's lead author Dr. Ezra Cohen.

October 26, 2017

UC San Diego Health Researchers Help Launch Second Pancreas Cancer “Dream Team”

New 4-year, $7-million collaborative grant will focus on preventing the deadly disease, featuring Drs. Scott Lippman and Andy Lowy.

» More Press

2018 Symposium

The 14th Moores Cancer Center Industry/Academia Translational Oncology Symposium will be held on Thursday, February 22, 2018. Learn more here.

Duane Roth Award Lecture
Engineered T-Cells: The Sky's the Limit

Carl June, MD

Richard W. Vague Professor Of Immunotherapy
Perelman School Of Medicine
University Of Pennsylvania

Keynote Speaker
A New Model for Translational Research in the Nonprofit Sector

Peter Schultz, PhD

Chief Executive Officer
California Institute for Biomedical Research

Opening Remarks
Ida Deichaite, PhD, UC San Diego Moores Cancer Center

Mutational Signatures for Cancer Treatment and Cancer Prevention
Ludmil Alexandrov, PhD, UC San Diego Moores Cancer Center

David Brenner, UC San Diego SOM & Health Sciences

Dual PI3K/BRD4 Inhibition as a Novel Therapeutic Strategy for Hepatocellular Carcinoma
Adam Burgoyne, MD, PhD, UC San Diego Moores Cancer Center

The New Generation of Antibody Drug Conjugates: Intersection of Target and Payload
Julia Coronella, PhD, Tanabe Research Labs

Moores Cancer Center Overview
Ezra Cohen, MD, UC San Diego Moores Cancer Center

Symposium Introduction
Ida Deichaite, PhD, UC San Diego Moores Cancer Center

In silico drug discovery of dual inhibitors of combinatorial synthetic lethality inhibitors in the era of precision medical oncology; proof of concept
Donald Durden, MD, PhD, UC San Diego Moores Cancer Center

Role of neutrophil-mediated inflammation in colorectal cancer
Napoleone Ferrara, MD, UC San Diego Moores Cancer Center

A Personalized Cancer Immunotherapy Paradigm: Simple solutions to address complex options for patients
Priti Hedge, PhD, Genentech

The Next Wave: BCMA Targeted CAR-T Cells for Multiple Myeloma
Kristen Hege, MD, Celgene

Moores Cancer Center Introduction
Scott Lippman, MD, UC San Diego Moores Cancer Center

Inhibition of Difficult to Drug Tumor Cell and Immuno-Oncology targets with Next Generation Antisense Inhibitors
Robert MacLeod, PhD, Ionis Pharmaceuticals

Systematic Mapping of Genetic Vulnerabilities in Cancer via Novel CRISPR-Cas9 Screening Methodologies
Prashant Mali, PhD, UC San Diego Moores Cancer Center

Brian McCloskey, Patient Advocate

Rana McKay, MD, UC San Diego Moores Cancer Center

Bryce Olson, Patient Advocate

Gene Control Approach to Manipulate Cell State: Sensitizing Cancer Cells to Antibody-mediated Attack
Dave Orlando, PhD, Syros Pharmaceuticals

Killing Cancer Stem Cells
Jeremy Rich, MD, UC San Diego Moores Cancer Center

2017 Symposium

Take a look at featured talks from the past symposium.

2015 Symposium Slideshow

Thank you to all that came and participated in the 2015 Symposium - we hope you enjoy the memories!

2014 Translational Oncology Symposium

A decade of fostering collaborations, fueling innovation & saving lives

San Diego ABC 10 News reporter Michael Chen interviewed San Diego resident Heather Clark, a patient of Moores Cancer Center, along with Ida Deichaite, Director of Industry Relations & Symposium Organizer, in a video report about the I-SPY Clinical Trial and Symposium. The I-SPY Clinical Trial is lead by Symposium Keynote Speaker and Principle Investigator Laura Esserman, MD, MBA. For the video, see below.

The article is available here.

  • Xconomy’s San Diego Life Sciences Roundup included Bob Klein’s Proposal presented at the Moores Cancer Center Symposium, outlining the $5 billion ballot initiative for funding California Institute for Regenerative Medicine in 2016.
         » Read Here
  • Xconomy's San Diego Life Sciences Roundup also included the Moores Cancer Center Symposium and Laura Esserman's acceptance of the Duane Roth Award.
         » Read Here
  • The San Diego Daily Transcript published an article about Dr. Esserman's acceptance of the Duane Roth Award and the Symposium.
         » Read Here
  • The San Diego Union Tribune wrote an article on the Symposium, namely the iSPY Trial and patient from the trial, San Diego Resident Heather Clark.
         » Read Here
  • Symposium Speaker Bob Klein was featured in a San Diego Union Tribune article, outlining the $5 billion ballot initiative for funding California Institute for Regenerative Medicine in 2016, presented at the Moores Cancer Center Symposium.
         » Read Here

Our Symposium Page

9th Symposium Featured on San Diego ABC 10 News

San Diego ABC 10 News reporter Michael Chen interviewed San Diego resident Linda Lowe, a patient of Moores Cancer Center Investigator Dr. Catriona Jamieson, along with Moores Cancer Center Director of Industry Relations Ida Deichaite, PhD , in a video report from the 6PM News on April 11 covering the successful 9th Industry/Academia Translational Oncology Symposium.

More In the Press